These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 19931261)

  • 1. An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
    Kucherlapati MH; Lee K; Nguyen AA; Clark AB; Hou H; Rosulek A; Li H; Yang K; Fan K; Lipkin M; Bronson RT; Jelicks L; Kunkel TA; Kucherlapati R; Edelmann W
    Gastroenterology; 2010 Mar; 138(3):993-1002.e1. PubMed ID: 19931261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide increases the number of mismatch repair-deficient intestinal crypts and accelerates tumorigenesis in a mouse model of Lynch syndrome.
    Wojciechowicz K; Cantelli E; Van Gerwen B; Plug M; Van Der Wal A; Delzenne-Goette E; Song JY; De Vries S; Dekker M; Te Riele H
    Gastroenterology; 2014 Nov; 147(5):1064-72.e5. PubMed ID: 25088490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A knockout for Lynch syndrome.
    Boland CR
    Gastroenterology; 2010 Mar; 138(3):820-2. PubMed ID: 20102757
    [No Abstract]   [Full Text] [Related]  

  • 4. Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2(loxP/loxP) Villin-Cre mice.
    Kortüm B; Campregher C; Lang M; Khare V; Pinter M; Evstatiev R; Schmid G; Mittlböck M; Scharl T; Kucherlapati MH; Edelmann W; Gasche C
    Gut; 2015 Dec; 64(12):1905-12. PubMed ID: 25429050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells.
    Bommi PV; Bowen CM; Reyes-Uribe L; Wu W; Katayama H; Rocha P; Parra ER; Francisco-Cruz A; Ozcan Z; Tosti E; Willis JA; Wu H; Taggart MW; Burks JK; Lynch PM; Edelmann W; Scheet PA; Wistuba II; Sinha KM; Hanash SM; Vilar E
    Cancer Res; 2021 May; 81(10):2760-2773. PubMed ID: 34003775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of MMR and TGFBR2 Increases the Susceptibility to Microbiota-Dependent Inflammation-Associated Colon Cancer.
    Tosti E; Almeida AS; Tran TTT; Barbachan E Silva M; Broin PÓ; Dubin R; Chen K; Beck AP; Mclellan AS; Vilar E; Golden A; O'Toole PW; Edelmann W
    Cell Mol Gastroenterol Hepatol; 2022; 14(3):693-717. PubMed ID: 35688320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
    Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
    Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
    Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
    Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced mRNA expression in paraffin-embedded tissue identifies MLH1- and MSH2-deficient colorectal tumours and potential mutation carriers.
    Müller A; Zielinski D; Friedrichs N; Oberschmid B; Merkelbach-Bruse S; Schackert HK; Linnebacher M; von Knebel Doeberitz M; Büttner R; Rüschoff J;
    Virchows Arch; 2008 Jul; 453(1):9-16. PubMed ID: 18581137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse models for hereditary nonpolyposis colorectal cancer.
    de Wind N; Dekker M; van Rossum A; van der Valk M; te Riele H
    Cancer Res; 1998 Jan; 58(2):248-55. PubMed ID: 9443401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.
    Kloor M; Huth C; Voigt AY; Benner A; Schirmacher P; von Knebel Doeberitz M; Bläker H
    Lancet Oncol; 2012 Jun; 13(6):598-606. PubMed ID: 22552011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis.
    Reitmair AH; Cai JC; Bjerknes M; Redston M; Cheng H; Pind MT; Hay K; Mitri A; Bapat BV; Mak TW; Gallinger S
    Cancer Res; 1996 Jul; 56(13):2922-6. PubMed ID: 8674041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stromal Indian hedgehog signaling is required for intestinal adenoma formation in mice.
    Büller NV; Rosekrans SL; Metcalfe C; Heijmans J; van Dop WA; Fessler E; Jansen M; Ahn C; Vermeulen JL; Westendorp BF; Robanus-Maandag EC; Offerhaus GJ; Medema JP; D'Haens GR; Wildenberg ME; de Sauvage FJ; Muncan V; van den Brink GR
    Gastroenterology; 2015 Jan; 148(1):170-180.e6. PubMed ID: 25307863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional expression of mutated K-ras accelerates intestinal tumorigenesis in Msh2-deficient mice.
    Luo F; Brooks DG; Ye H; Hamoudi R; Poulogiannis G; Patek CE; Winton DJ; Arends MJ
    Oncogene; 2007 Jun; 26(30):4415-27. PubMed ID: 17297472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents.
    Bodo S; Colas C; Buhard O; Collura A; Tinat J; Lavoine N; Guilloux A; Chalastanis A; Lafitte P; Coulet F; Buisine MP; Ilencikova D; Ruiz-Ponte C; Kinzel M; Grandjouan S; Brems H; Lejeune S; Blanché H; Wang Q; Caron O; Cabaret O; Svrcek M; Vidaud D; Parfait B; Verloes A; Knappe UJ; Soubrier F; Mortemousque I; Leis A; Auclair-Perrossier J; Frébourg T; Fléjou JF; Entz-Werle N; Leclerc J; Malka D; Cohen-Haguenauer O; Goldberg Y; Gerdes AM; Fedhila F; Mathieu-Dramard M; Hamelin R; Wafaa B; Gauthier-Villars M; Bourdeaut F; Sheridan E; Vasen H; Brugières L; Wimmer K; Muleris M; Duval A;
    Gastroenterology; 2015 Oct; 149(4):1017-29.e3. PubMed ID: 26116798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
    Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-Hodgkin lymphoma related to hereditary nonpolyposis colorectal cancer in a patient with a novel heterozygous complex deletion in the MSH2 gene.
    Pineda M; Castellsagué E; Musulén E; Llort G; Frebourg T; Baert-Desurmont S; González S; Capellá G; Blanco I
    Genes Chromosomes Cancer; 2008 Apr; 47(4):326-32. PubMed ID: 18181177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.
    Planck M; Ericson K; Piotrowska Z; Halvarsson B; Rambech E; Nilbert M
    Cancer; 2003 Mar; 97(6):1551-7. PubMed ID: 12627520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutator phenotype in Msh2-deficient murine embryonic fibroblasts.
    Reitmair AH; Risley R; Bristow RG; Wilson T; Ganesh A; Jang A; Peacock J; Benchimol S; Hill RP; Mak TW; Fishel R; Meuth M
    Cancer Res; 1997 Sep; 57(17):3765-71. PubMed ID: 9288785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.